CCL2 and inflammatory bowel disease: When we restricted the analysis to each IBD groups, we found in CD, that levels of MCP-1 at enrolment were significantly higher in stable patients (remission group) compared to unstable patients developing a relapse during follow-up (relapsing group) (P<0.04, Fig 2B).